ArticleFrontiers in oncology2022

Anti-PD-1 Monoclonal Antibody Combined With Anti-VEGF Agent Is Safe and Effective in Patients With Recurrent/Metastatic Head and Neck Squamous Cancer as Second-Line or Beyond Treatment.

Yonghong Hua et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.